title: Biosimilar therapies in inflammatory bowel disease: should we care about patient profile?
authors.affiliation: a IBD Center, Department of Gastroenterology , Humanitas Research Hospital , Rozzano, Milan , Italy.
authors.forename: Gionata
authors.initials: G
authors.lastname: Fiorino
authors.affiliation: b Pharmacy , Humanitas Research Hospital , Rozzano, Milan , Italy.
authors.forename: Maria
authors.initials: M
authors.lastname: Fazio
authors.affiliation: c Department of Biomedical Sciences , Humanitas University , Rozzano, Milan , Italy.
authors.forename: Silvio
authors.initials: S
authors.lastname: Danese
mesh_terms: D059451:Biosimilar Pharmaceuticals / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D017281:Cost of Illness; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000191:economics; D000069285:Infliximab / Q000191:economics / Q000627:therapeutic use*; D018802:Patient-Centered Care
chemical_list: D059451:Biosimilar Pharmaceuticals; D000069285:Infliximab